middle.news
Immuron Advances Travelan® with Strong Phase 2 Data and FDA Submission
7:03pm on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Immuron Advances Travelan® with Strong Phase 2 Data and FDA Submission
7:03pm on Monday 2nd of June, 2025 AEST
Key Points
Phase 2 study shows Travelan® reduces ETEC antigen exposure with significant immunological markers
Statistically significant faster clearance of pathogenic ETEC bacteria observed
Travelan® group exhibited improved gut microbiome diversity and increased beneficial bacteria
Clinical Study Report submitted to FDA; end-of-Phase 2 meeting planned
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immuron (ASX:IMC)
OPEN ARTICLE